Enzyme‐Instructed Nanofibrous Assemblies Enable Targeted PROTAC Release for Cancer Therapy
Advanced Healthcare Materials · 2026-05 · 15 (18)
DOI: 10.1002/adhm.202505105 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 24.02.2026. Verfasst von Yuchen Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: New Cornerstone Science Laboratory, Department of Chemistry, Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Tsinghua Universit…. Hauptthemen laut MEDLINE: Nanofibers, Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: The New Cornerstone Foundation, the Science Fund for Excellent Research Groups (Category A), Fundamental and Interdisciplinary Disciplines Breakthrough Plan of the Ministry of Education of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Proteolysis‐targeting chimeras (PROTACs) have emerged as a promising strategy for the selective degradation of oncoproteins, offering significant potential in cancer therapy, yet their clinical translation is impeded by the inherent limitations, including high hydrophobicity, poor cellular permeability, and inadequate tumor‐targeting efficiency. To address these challenges, we developed a rationally engineered peptide conjugate, Nap‐Lys(ARV‐771)‐Tyr(H 2 PO 3 )‐Phe‐Phe‐OH (NapYp‐ARV), to enhance the bioavailability and therapeutic efficacy of PROTACs through sequential enzyme‐instructed self‐assembly (EISA) and activation. Upon intratumoral phosphatase‐mediated dephosphorylation, NapYp‐ARV self‐assembles into nanofibers that enhance tumor accumulation. Following cellular internalization, carboxylesterase‐catalyzed hydrolysis liberates the PROTAC payload ARV‐771, inducing potent BRD4 degradation and consequent apoptosis. In vivo, NapYp‐ARV administration achieved higher tumor drug concentration than free ARV‐771, driving robust protein degradation and tumor regression while maintaining hematological and histological safety. Collectively, this EISA‐based delivery platform offers a versatile strategy to advance targeted PROTAC therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- New Cornerstone Science Laboratory, Department of Chemistry, Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Tsinghua University, Beijing, China.
- Beijing Life Science Academy, Beijing, China.
- School of Biomedical Sciences, Hunan University, Changsha, Hunan, China.
- Center For BioAnalytical Chemistry, Hefei National Laboratory of Physical Science at Microscale, University of Science and Technology of China, Hefei, China.
ORCID-Profile: Jinghong Li
Förderung
- The New Cornerstone Foundation, the Science Fund for Excellent Research Groups (Category A)
- Fundamental and Interdisciplinary Disciplines Breakthrough Plan of the Ministry of Education of China
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Beijing Life Science Academy Initiative Scientific Research Program
Zitieren
APA
Yang, Y., Yang, C., Fu, Z., Pan, M., Wu, L., Hou, H., & Li, J. (2026). Enzyme‐Instructed Nanofibrous Assemblies Enable Targeted PROTAC Release for Cancer Therapy. Advanced Healthcare Materials, 15(18). https://doi.org/10.1002/adhm.202505105
Vancouver
Yang Y, Yang C, Fu Z, Pan M, Wu L, Hou H, et al. Enzyme‐Instructed Nanofibrous Assemblies Enable Targeted PROTAC Release for Cancer Therapy. Advanced Healthcare Materials. 2026;15(18). doi:10.1002/adhm.202505105
BibTeX
@article{Yang2026,
author = {Yang, Yuchen and Yang, Chunrong and Fu, Zongliang and Pan, Meichen and Wu, Libing and Hou, Hongwei and Li, Jinghong},
title = {Enzyme‐Instructed Nanofibrous Assemblies Enable Targeted PROTAC Release for Cancer Therapy},
journal = {Advanced Healthcare Materials},
year = {2026},
volume = {15},
number = {18},
doi = {10.1002/adhm.202505105}
}
EUVIMED